| Identification | Back Directory | [Name]
Losigamone | [CAS]
112856-44-7 | [Synonyms]
AO33 AO-33 AO 33 losigame Losigamon ADD137022 ADD-137022 Losigamone ADD 137022 5-[(2-Chlorophenyl)hydroxymethyl]-4-methoxyfuran-2(5H)-one 2(5H)-Furanone, 5-[(R)-(2-chlorophenyl)hydroxymethyl]-4-methoxy-, (5S)-rel- | [Molecular Formula]
C12H11ClO4 | [MDL Number]
MFCD00871710 | [MOL File]
112856-44-7.mol | [Molecular Weight]
254.67 |
| Chemical Properties | Back Directory | [Boiling point ]
480.1±45.0 °C(Predicted) | [density ]
1.39±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
12.32±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Losigamone (AO-33) is an orally active antiepileptic compound. Losigamone blocks sodium channel. Losigamone stimulates the neuronal chloride channel and enhance chloride influx. Losigamone potentiates GABA-mediated responses and reduces epileptiform activity induced by chloride channel antagonists. Losigamone can be used for epilepsy research[1][2]. | [References]
[1] Chen H, et al. Losigamone add-on therapy for focal epilepsy. Cochrane Database Syst Rev. 2019 Dec 11;12(12):CD009324. DOI:10.1002/14651858.CD009324.pub5 [2] Jones FA, et al. The anticonvulsant effects of the enantiomers of losigamone. Br J Pharmacol. 1999 Nov;128(6):1223-8. DOI:10.1038/sj.bjp.0702919 |
|
|